Investigation of the differences between various renal tumor portions in MRI and tissue examination
Summary description of the study
The therapy and prognosis of renal tumors strongly depend on the exact tumor type, which is determined by biopsy, especially in patients whose tumors have already formed metastases and in very old and sick patients. Due to possible differences between various tumor portions, assessment based on a single tissue sample is often difficult. Magnetic resonance imaging (MRI) allows for a very precise representation of the tumor. Thanks to new techniques, statements about the tissue composition in the tumor are also possible, which could provide insights into its aggressiveness and thus the patient's prognosis. This could enable targeted tissue samples from the most aggressive portions and thus a better assessment of the prognosis.
(BASEC)
Intervention under investigation
Patients included in the study will undergo an MRI examination, which will include not only standard sequences but also some new study techniques. No additional contrast agent will be administered.
(BASEC)
Disease under investigation
The study aims to improve the diagnostic assessment of renal tumors.
(BASEC)
The following patients may be included in the study: - Patients suspected of having a renal tumor with a minimum size of approximately 2 cm - Patient age ≥ 18 years - Patient's consent to the study (BASEC)
Exclusion criteria
Patients who meet any of the following statements unfortunately cannot participate in the study: - Pregnant or breastfeeding women - Lack of ability to participate in the study due to language problems, mental illnesses, dementia, etc. - Presence of non-MRI-compatible metallic or electronic implants (pacemakers, shrapnel or other metallic foreign bodies, neurostimulators, etc.). (BASEC)
Trial sites
Zurich
(BASEC)
Sponsor
University Hospital Zurich
(BASEC)
Contact
Contact Person Switzerland
PD Dr. A. Hötker
+41 43 254 41 10
radiologie@clutterusz.chUniversity Hospital Zurich
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Zurich
(BASEC)
Date of authorisation
05.08.2022
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
Tumor heterogeneity of renal tumors assessed by multiparametric MRI with direct radiological-histopathological correlation: an explorative study (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available